Emmaus Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

SELECTED FINANCIAL STATEMENT ASSETS

SELECTED FINANCIAL STATEMENT ASSETS

12 Months Ended

Dec. 31, 2023

Balance Sheet Related Disclosures [Abstract]

SELECTED FINANCIAL STATEMENT ASSETS

NOTE 4—SELECTED FINANCIAL STATEMENT ASSETS

Inventories consisted of the following (in thousand):


	As of December 31
	2023			2022
Raw materials and components	$	1,329		$	1,393
Work-in-process		186			513
Finished goods		5,163			5,428
Inventory reserve		(4,967	)		(4,955	)
Total inventories, net	$	1,711		$	2,379

Prepaid expenses and other current assets consisted of the following (in thousands):


	As of December 31
	2023		2022
Prepaid insurance	$	595	$	598
Prepaid expenses		536		467
Other current assets		596		449
Total prepaid expenses and other current assets	$	1,727	$	1,514

Property and equipment consisted of the following (in thousands):


	As of December 31
	2023			2022
Equipment	$	383		$	367
Leasehold improvements		39			39
Furniture and fixtures		99			99
Total property and equipment		521			505
Less: accumulated depreciation		(462	)		(430	)
Total property and equipment, net	$	59		$	75

For the years ended December 31, 2023 and 2022, depreciation expenses were approximately $32,000 and $39,000, respectively reported in general and administrative expenses in the consolidated statements of operations.